Vol. 27 No. 2 (2023): In focus: CardioOncology
CARDIOONCOLOGY

Risk factors for venous thromboembolism in glioma patients

pdf (Русский)
  • K.A. Pishchulov,
  • M.A. Simakova,
  • V.L. Lukinov,
  • S.I. Parkhomenko,
  • N.E. Voinov,
  • S.S. Sklyar,
  • O.M. Moiseeva
K.A. Pishchulov
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
Bio
M.A. Simakova
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
V.L. Lukinov
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg; Siberian State University of Telecommunications and Information Science, Novosibirsk
S.I. Parkhomenko
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
N.E. Voinov
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
S.S. Sklyar
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
O.M. Moiseeva
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine, Saint Petersburg
Concomitant disease in glioma patients
DOI: https://doi.org/10.21688/1681-3472-2023-2-7-18

Published 2023-06-30

Keywords

  • Central Nervous System Neoplasms,
  • Glioma,
  • Retrospective Studies,
  • Venous Thromboembolism,
  • Venous Thrombosis

How to Cite

Pishchulov, K., Simakova, M., Lukinov, V., Parkhomenko, S., Voinov, N., Sklyar, S., & Moiseeva, O. (2023). Risk factors for venous thromboembolism in glioma patients. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 27(2), 7–18. https://doi.org/10.21688/1681-3472-2023-2-7-18

Copyright (c) 2023 Pishchulov K.A., Simakova M.A., Lukinov V.L., Parkhomenko S.I., Voinov N.E., Sklyar S.S., Moiseeva O.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background: Ranking third in the cause of death structure, venous thromboembolism (VTE) is a frequent complication in patients with central nervous system tumors.
Objective: To assess the incidence of venous thrombosis and its risk factors in glioma patients based on retrospective data.
Methods: Our retrospective study included 186 glioma patients from the Neurosurgery Department of Almazov National Medical Research Centre.
Results: The VTE incidence was 8% in patients with brain neoplasms. Comparative analysis of 2 groups to identify VTE predictors showed that the probability of thrombosis increases with factors leading to the patient immobilization: altered mental status (40% [n = 6] in the VTE group vs 18% [n = 30] in the non-VTE group, OR: 3.1 [95% СI: 0.8–10.6], P = .080), neurological deficit (67% [n = 50] vs 29% [n = 10], OR: 4.8 [95% СI: 1.4–18.7], P = .007), and bed rest for more than 3 days (33% vs 4%, OR: 13.1 [95% СI: 2.7–62.8], P < .001). Based on the validation results, Caprini and IMPROVEDD risk scores have high negative predictive values: 0.99 [95% СI: 0.93–1.00] vs 0.97 [95% СI: 0.93–0.99] (P = .317). Caprini risk score has a specificity of 48.2% and a sensitivity of 93.3% (AUC = 78.98); the threshold value for high-risk VTE detection is 5.5 points. IMPROVEDD risk score has a specificity of 82.5% and a sensitivity of 73.3% (AUC = 81.1); the threshold value for high-risk VTE detection is 4.5 points.
Conclusion: Our study revealed VTE risk factors in glioma patients, such as neurological deficit, prolonged bed rest (more than 3 days), and a high-grade tumor. We demonstrated high negative predictive values of Caprini and IMPROVEDD risk scores and determined their threshold values to be validated in a further prospective study. Due to the high incidence of VTE and risks of hemorrhage in patients with central nervous system tumors, personalized venous thrombosis risk calculators should be developed, providing for features of thrombosis pathogenesis in this patient group.

Received 12 December 2022. Revised 7 April 2023. Accepted 31 May 2023.

Funding: The study was supported by Ministry of Science and Higher Education of Russian Federation (No. 075-15-2022-301).

Conflict of interest: The authors declare no conflict of interest.

Contribution of the authors
Conception and study design: K.A. Pishchulov, M.A. Simakova
Data collection and analysis: K.A. Pishchulov, S.I. Parkhomenko
Statistical analysis: V.L. Lukinov
Drafting the article: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. Moiseeva
Critical revision of the article: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. Moiseeva
Final approval of the version to be published: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. Moiseeva

pdf (Русский)

References

  1. Lyman G.H., Carrier M., Ay C., Di Nisio M., Hicks L.K., Khorana A.A., Leavitt A.D., Lee A.Y.Y., Macbeth F., Morgan R.L., Noble S., Sexton E.A., Stenehjem D., Wiercioch W., Kahale L.A., Alonso-Coello P. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. PMID: 33570602; PMCID: PMC7903232. https://doi.org/10.1182/bloodadvances.2020003442
  2. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. PMID: 17918266. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.23062
  3. Ostrom Q.T., Cioffi G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(Suppl 5):v1-v100. PMID: 31675094; PMCID: PMC6823730. https://doi.org/10.1093/neuonc/noz150
  4. Riedl J., Ay C. Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost. 2019;45(4):334-341. PMID: 31041803; PMCID: PMC6548560. https://doi.org/10.1055/s-0039-1688493
  5. Riedl J., Preusser M., Nazari P.M.S., Posch F., Panzer S., Marosi C., Birner P., Thaler J., Brostjan C., Lötsch D., Berger W., Hainfellner J.A., Pabinger I., Ay C. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129(13):1831-1839. PMID: 28073783; PMCID: PMC5823234. https://doi.org/10.1182/blood-2016-06-720714
  6. Horsted F., West J., Grainge M.J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. PMID: 22859911; PMCID: PMC3409130. https://doi.org/10.1371/journal.pmed.1001275
  7. Бервицкий А.В., Гужин В.Э., Мойсак Г.И., Бабченко В.Я., Рзаев Д.А. Тромбоэмболические осложнения в нейрохирургии: решения на границе возможного и необходимого (обзор литературы). Нейрохирургия. 2020;22(4):112-122. https://doi.org/10.17650/1683-3295-2020-22-4-112-122 Bervitskiy A.V., Guzhin V.E., Moisak G.I., Babchenko V.Y., Rzaev D.A. Thromboembolic complications in neurosurgery: solutions at the boundaries of possible and necessary (review). Russian Journal of Neurosurgery. 2020;22(4):112-122. (In Russ.) https://doi.org/10.17650/1683-3295-2020-22-4-112-122
  8. Wen P.Y., Packer R.J. The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro Oncol. 2021;23(8):1215-1217. PMID: 34185090; PMCID: PMC8328017. https://doi.org/10.1093/neuonc/noab120
  9. Semrad T.J., O’Donnell R., Wun T., Chew H., Harvey D., Zhou H., White R.H. Epidemiology of venous thromboembolism in 9 489 patients with malignant glioma. J Neurosurg. 2007;106(4):601-608. PMID: 17432710. https://doi.org/10.3171/jns.2007.106.4.601
  10. Streiff M.B., Holmstrom B., Angelini D., Ashrani A., Elshoury A., Fanikos J., Fertrin K.Y., Fogerty A.E., Gao S., Goldhaber S.Z., Gundabolu K., Ibrahim I., Kraut E., Leavitt A.D., Lee A., Lee J.T., Lim M., Mann J., Martin K., McMahon B., Moriarty J., Morton C., Ortel T.L., Paschal R., Schaefer J., Shattil S., Siddiqi T., Sudheendra D., Williams E., Hollinger L., Nguyen M.Q. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(10):1181-1201. PMID: 34666313. Available from: https://www.thebloodproject.com/wp-content/uploads/2021/10/NCCN_VTE.pdf
  11. Lyman G.H., Khorana A.A., Kuderer N.M., Lee A.Y., Arcelus J.I., Balaban E.P., Clarke J.M., Flowers C.R., Francis C.W., Gates L.E., Kakkar A.K., Key N.S., Levine M.N., Liebman H.A., Tempero M.A., Wong S.L., Prestrud A.A., Falanga A.; American Society of Clinical Oncology clinical practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. PMID: 23669224. https://doi.org/10.1200/JCO.2013.49.1118
  12. Key N.S., Khorana A.A., Kuderer N.M., Bohlke K., Lee A.Y.Y., Arcelus J.I., Wong S.L., Balaban E.P., Flowers C.R., Francis C.W., Gates L.E., Kakkar A.K., Levine M.N., Liebman H.A., Tempero M.A., Lyman G.H., Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520. PMID: 31381464. https://doi.org/10.1200/JCO.19.01461
  13. Diaz M., Jo J. Venous thrombotic events and anticoagulation in brain tumor patients. Curr Oncol Rep. 2022;24(4):493-500. PMID: 35179708. https://doi.org/10.1007/s11912-021-01178-9
  14. Raskob G.E., van Es N., Verhamme P., Carrier M., Di Nisio M., Garcia D., Grosso M.A., Kakkar A.K., Kovacs M.J., Mercuri M.F., Meyer G., Segers A., Shi M., Wang T.-F., Yeo E., Zhang G., Zwicker J.I., Weitz J.I., Büller H.R.; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. PMID: 29231094. https://doi.org/10.1056/NEJMoa1711948
  15. Carney B.J., Uhlmann E.J., Puligandla M., Mantia C., Weber G.M., Neuberg D.S., Zwicker J.I. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019;17(1):72-76. https://doi.org/10.1111/jth.14336
  16. Wang Z.-Y., Wan Y.-D., Liu X.-Z., Wang H., Jiang G.-Y., Yang B. A single-center, randomized, double-blind study of 94 patients undergoing surgery for cerebral glioma to compare postoperative thromboprophylaxis with and without rivaroxaban. Med Sci Monit. 2022;28:e934341. PMID: 35140195; PMCID: PMC8845378. https://doi.org/10.12659/MSM.934341
  17. Thomas A.A., Wright H., Chan K., Ross H., Prasad P., Goodwin A., Holmes C.E. Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma. J Thromb Thrombolysis. 2022;53(2):479-484. PMID: 34347201. https://doi.org/10.1007/s11239-021-02537-w
  18. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. PMID: 36017568. https://doi.org/10.1093/eurheartj/ehac244
  19. Bernstein M., Berger M.S. Neuro-Oncology: The Essentials. 3rd ed. New York: Thieme; 2014. 616 p.
  20. Perry J.R. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012;14 Suppl 4(Suppl 4):iv73-80. PMID: 23095833; PMCID: PMC3480243. https://doi.org/10.1093/neuonc/nos197
  21. Tawil N., Bassawon R., Meehan B., Montermini L., Nehme A., Choi D., Adnani L., Spinelli C., Mackman N., Riazalhosseini Y., Najafabadi H., Rak J. Podoplanin and tissue factor cooperate in triggering microthrombosis in experimental glioblastoma and are released to systemic circulation as cargo of extracellular vesicles. ISTH Congress Abstracts. Available from: https://abstracts.isth.org/abstract/podoplanin-and-tissue-factor-cooperate-in-triggering-microthrombosis-in-experimental-glioblastoma-and-are-released-to-systemic-circulation-as-cargo-of-extracellular-vesicles (accessed 16 Oct 2022)
  22. Tawil N., Bassawon R., Meehan B., Nehme A., Montermini L., Gayden T., De Jay N., Spinelli C., Chennakrishnaiah S., Choi D., Adnani L., Zeinieh M., Jabado N., Kleinman C.L., Witcher M., Riazalhosseini Y., Key N.S., Schiff D., Grover S.P., Mackman N., Couturier C.P., Petrecca K., Suvà M.L., Patel A., Tirosh I., Najafabadi H., Rak J. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021;5(6):1682-1694. PMID: 33720339; PMCID: PMC7993100. https://doi.org/10.1182/bloodadvances.2020002998
  23. Suzuki-Inoue K., Kato Y., Inoue O., Kaneko M.K., Mishima K., Yatomi Y., Yamazaki Y., Narimatsu H., Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282(36):25993-26001. PMID: 17616532. https://doi.org/10.1074/jbc.M702327200
  24. Sawaya R., Zuccarello M., Elkalliny M., Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol. 1992;14(2):119-125. PMID: 1331348. https://doi.org/10.1007/BF00177615
  25. Розанов И.Д., Шириков Е.И., Балканов А.С., Гаганов Л.Е., Василенко И.А. Некоторые закономерности, определяющие уровень D-димера крови после резекции злокачественной глиомы головного мозга. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2017;81(6):64-68. https://doi.org/10.17116/neiro201781664-68 Rozanov I.D., Shirikov E.I., Balkanov A.S., Gaganov L.E., Vasilenko I.A. Some features controlling the blood D-dimer level after resection of malignant brain glioma. Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko = Burdenko's Journal of Neurosurgery. 2017;81(6):64-68. (In Russ.) https://doi.org/10.17116/neiro201781664-68
  26. Passamonti S.M., Artoni A., Carrabba G., Merati G., Abbattista M., Capecchi M., Castellani M., Marenghi C., Trombetta E., Giammattei L., Caroli M., Bucciarelli P., Scalambrino E., Peyvandi F., Martinelli I. Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study. J Thromb Thrombolysis. 2021;52(1):224-231. PMID: 33837918. https://doi.org/10.1007/s11239-021-02441-3
  27. Unruh D., Schwarze S.R., Khoury L., Thomas C., Wu M., Chen L., Chen R., Liu Y., Schwartz M.A., Amidei C., Kumthekar P., Benjamin C.G., Song K., Dawson C., Rispoli J.M., Fatterpekar G., Golfinos J.G., Kondziolka D., Karajannis M., Pacione D., Zagzag D., McIntyre T., Snuderl M., Horbinski C. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917-930. PMID: 27664011; PMCID: PMC5640980. https://doi.org/10.1007/s00401-016-1620-7
  28. Melnichnikova O., Zhilenkova Y., Sirotkina O., Zolotova E., Pishchulov K., Tastanbekov M., Paltsev A., Simakova M. Circulating small extracellular vesicles profiling and thrombin generation as potential markers of thrombotic risk in glioma patients. Front Cardiovasc Med. 2022;9:789937. PMID: 35811733; PMCID: PMC9259782. https://doi.org/10.3389/fcvm.2022.789937
  29. Мельничникова О.С., Жиленкова Ю.И., Золотова Е.А., Пищулов К.А., Сироткина О.В., Симакова М.А., Вавилова Т.В. Тест генерации тромбина как интегральный анализ системы гемостаза: технические возможности и применение в клинико-лабораторной практике. Российский журнал персонализированной медицины. 2022;2(3):119-128. https://doi.org/10.18705/2782-3806-2022-2-3-119-128 Melnichnikova O.S., Zhilenkova Y.I., Zolotova E.A., Pishchulov K.A., Sirotkina O.V., Simakova M.A., Vavilova T.V. Thrombin generation test as an integral analysis of the hemostasis system: technical capabilities and application in laboratory practice. Russian Journal for Personalized Medicine. 2022;2(3):119-128. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-3-119-128
  30. Pannucci C.J., Fleming K.I. Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score. J Vasc Surg Venous Lymphat Disord. 2018;6(3):304-311. PMID: 29452956. https://doi.org/10.1016/j.jvsv.2017.10.016
  31. Golemi I., Salazar Adum J.P., Tafur A., Caprini J. Venous thromboembolism prophylaxis using the Caprini score. Dis Mon. 2019;65(8):249-298. PMID: 30638566. https://doi.org/10.1016/j.disamonth.2018.12.005